Development of an intractable disease treatment between Heurim Biocell Co., Ltd. and
GHIC Group in China.
A business agreement between Heurim Biocell Co., Ltd. and GHIC Group in China on the
development and rehabilitation of intractable disease treatments.
Heurim Biocell Co., Ltd. (CEO Choi Joon-woo) announced that it will sign a memorandum of understanding (MOU) with China's
GHIC Group for the treatment and rehabilitation of intractable diseases. Based on
mutual active cooperation, it will provide know-how for rehabilitation treatment services and at the same time strive to develop
treatments for intractable diseases.
The gist of the agreement is that China's entry into the medical giant market and
that small and medium-sized bio companies in Korea can overcome long-term investments from financial institutions or other investment institutions, and
its size can also overcome limited weaknesses and draw long-term investments.
In other words, GHIC can enjoy the effect of killing two birds with one stone by
exporting know-how in rehabilitation services while receiving huge investment costs for the
development of intractable disease treatments from domestic bio companies.
Hyurim Biocell Co., Ltd. is a company with fat-derived substrate vascular separation separation devices and technology, and
has high-quality technologies such as autoimmune diseases such as arthritis and rheumatism,
treatment of necrosis, and symptom improvement and pain relief.
GHIC Group is a leading investment company expanding its industrial capital
investment in China to other industries, and is investing in the world's leading
companies such as LG, AstraZeneca, and Nippon Steel, and this upcoming MOU
with Hurim Biocell will invest in high bio-area companies in China and meet demand for rehabilitation treatment.
The ratio of doctors and rehabilitation therapists in China is 1:1.1, far below the
ratio of 1:5-10 in developed countries, expressing great interest in this field. If this agreement
and investment are made, the amount of investment in Korea will be about 1 trillion
won (KRW).
Once this agreement is completed, the two companies will also increase cooperation
in the area of cosmetic plastic surgery.
¢ßÈÞ¸²¹ÙÀÌ¿À¼¿°ú Áß±¹GHIC±×·ì°£ ³Ä¡¼º Áúȯġ·áÁ¦ °³¹ß ¹× ÀçÈ°Ä¡·á¿¡ °üÇѾ÷¹«Çù¾à
¢ßÈÞ¸²¹ÙÀÌ¿À¼¿(´ëÇ¥ÀÌ»ç ÃÖÁØ¿ì)Àº ³Ä¡¼º Áúȯ Ä¡·á¿Í ÀçÈ°Ä¡·á¸¦ À§ÇØ Áß±¹ÀÇ GHIC±×·ì°ú ¾÷¹«Çù¾à(MOU)À» ü°áÇÒ ¿¹Á¤À̶ó°í ¹àÇû´Ù. »óÈ£ Àû±ØÀûÀÎ Çù·ÂÀ» ¹ÙÅÁÀ¸·Î ÀçÈ°Ä¡·á ¼ºñ½º¸¦ À§ÇÑ ³ëÇϿ츦 Á¦°øÇÔ°ú µ¿½Ã¿¡ ³Ä¡¼º Áúȯġ·áÁ¦ °³¹ß¿¡µµ Èû¾µ ¿¹Á¤ÀÌ´Ù.
À̹ø Çù¾àÀÇ ¿äÁö´Â Áß±¹ÀÇ ÀÇ·á°Å´ë½ÃÀåÀÇ ÁøÃâ°ú, ±¹³»¿¡¼ Áß¼Ò¹ÙÀÌ¿À±â¾÷ÀÌ ±ÝÀ¶±â°üÀ̳ª ±×¿Ü ÅõÀÚ±â°üÀ¸·ÎºÎÅÍ Àå±âÀûÀÎ ÅõÀÚ¸¦ À̲ø¾î ³»±â ¾î·Æ°í ±× ±Ô¸ð ¶ÇÇÑ ÇÑÁ¤µÇÀÖ´Â ¾àÁ¡À» ±Øº¹ÇÏ°í Àå±âÀûÀÎ ÅõÀÚ¸¦ À̲ø¾î³¾¼ö Àִٴµ¥ ÀÖ´Ù.
Áï GHICÃøÀº ±¹³» ¹ÙÀÌ¿À±â¾÷À¸·ÎºÎÅÍ Áß±¹³»ÀÇ ÀçÈ°Ä¡·á¸¦ À§ÇÑ Ä¡·á»çÀÇ Àû±ØÀûÀÎ ¾ç¼º°ú ÁúÁÁÀº ¼ºñ¸¦ À§ÇÑ ³ëÇϿ츦,¢ßÈÞ¸²¹ÙÀÌ¿À¼¿Àº ³Ä¡¼º Áúȯġ·áÁ¦ °³¹ß¿¡ ´ëÇÑ ¸·´ëÇÑ ÅõÀÚºñ¿ëÀ» ¾ÈÁ¤ÀûÀ¸·Î °ø±Þ¹ÞÀ½°ú µ¿½Ã¿¡ ÀçÈ°Ä¡·á ¼ºñ½º¿¡ ´ëÇÑ ³ëÇÏ¿ì ¼öÃâÀ» ÅëÇØ ±â¾÷ÀÇ °¡Ä¡¸¦ ±Ø´ëÈ ½Ãų¼ö ÀÖ´Â Àϼ®ÀÌÁ¶ÀÇ È¿°ú¸¦ ´©¸±¼ö ÀÖ´Ù´Â °ÍÀÌ´Ù.
¢ßÈÞ¸²¹ÙÀÌ¿À¼¿Àº Áö¹æÀ¯·¡ ±âÁúÇ÷°üºÐȹ ºÐ¸®±â±â ¹× ±â¼ú·ÂÀ» º¸À¯ÇÑ ±â¾÷À̸ç, ¹Ì¿ë¼ºÇü ¿µ¿ª ¿Ü¿¡ °üÀý¿°, ·ù¸ÓƼÁò°ú °°Àº ÀÚ°¡¸é¿ª¼º Áúȯ, ±«»ç¼º Áúȯ Ä¡·á µî ÀûÀÀÁõ À¸·ÎÀÇ È®Àå, ¶ÇÇÑ Áõ»ó °³¼±°ú ÅëÁõ¿ÏÈ µî ±âÁúÇ÷°üºÐȹÀ» È°¿ëÇÑ Ã·´Ü Àç»ýÀÇÇÐ µîÀÇ Áú³ôÀº ±â¼ú·ÂÀ» º¸À¯ÇÑ Á¡ÀÌ GHIC±×·ì°úÀÇ Çù¾àÀ» À§ÇÑ °ü½ÉÀÇ ¿øµ¿·ÂÀÌ´Ù.
GHIC±×·ìÀº Áß±¹³»¿¡¼ »ê¾÷ÀÚº»ÀÇ ÅõÀÚ¸¦ ±âŸ»ê¾÷ºÐ¾ß±îÁö È®´ëÇÏ°í ÀÖ´Â ¼±µÎÅõÀÚ ±â¾÷À̸ç, LG,¾Æ½ºÆ®¶óÁ¦³×Ä«,½ÅÀϺ»Á¦Ã¶µî ¼¼°èÀ¯¼öÀÇ ±â¾÷µé¿¡ ÅõÀÚÇÏ°í ÀÖÀ¸¸ç ±Ý¹øÀÇ ¢ßÈÞ¸²¹ÙÀÌ¿À¼¿°úÀÇ ¿¹Á¤µÈ Çù¾à(MOU)Àº ±¹³»ÀÇ ³ôÀº ¹ÙÀÌ¿À¿µ¿ªÀÇ È¸»ç¿¡ ÅõÀÚÇÏ°í ÀçÈ°Ä¡·á¿¡ ´ëÇÑ Áß±¹³»ÀÇ ¼ö¿ä¸¦ ÃæÁ·½Ãų ¿¹Á¤ÀÌ´Ù.
Áß±¹³»ÀÇ ÀÇ»ç¿Í ÀçÈ°Ä¡·á»çÀÇ ºñÀ²Àº 1:1.1·Î¼ ¼±Áø±¹ÀÇ ºñÀ² 1:5~10¿¡ ÇÑÂü ¹Ì´ÞÇÏ´Â ¼öÁØÀ¸·Î À̺о߿¡ ´ëÇÑ Å« °ü½ÉÀ» Ç¥¸íÇÏ°í ÀÖ´Ù. ±Ý¹øÀÇ Çù¾à°ú ÅõÀÚ°¡ ¼º»çµÉ½Ã ±¹³»¿¡ ÅõÀڵǴ ±Ô¸ð´Â ¾à1Á¶¿ø(¿øÈ)Á¤µµÀÌ´Ù.
º» Çù¾àÀÌ ¿Ï¼ºµÇ¸é ¹Ì¿ë¼ºÇü ¿µ¿ª¿¡µµ ¾ç»çÀÇ Çù·ÂÀ» ³ôÀÏ ¿¹Á¤ÀÌ´Ù. |